IN.PACT Global Clinical Study
|ClinicalTrials.gov Identifier: NCT01609296|
Recruitment Status : Active, not recruiting
First Posted : May 31, 2012
Results First Posted : January 28, 2019
Last Update Posted : November 13, 2019
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Disease||Device: IN.PACT Admiral™ Drug Eluting Balloon||Not Applicable|
Peripheral artery disease (PAD) commonly results from progressive narrowing of the arteries in the lower extremities, usually due to atherosclerosis. Progression of PAD can result in critical limb ischemia (CLI), manifested by ischemic pain at rest or in the breakdown of the skin, resulting in ulcers or gangrene which ultimately may lead to amputation and death.
The IN.PACT Global Clinical Study aims to expand and understand the safety and efficacy data on the IN.PACT Admiral™ DEB in a real world population of subjects with intermittent claudication and/or rest pain (Rutherford class 2-3-4) due to obstructive disease of the superficial femoral and/or popliteal arteries.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1535 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The IN.PACT Global Clinical Study for the Treatment of Comprehensive Superficial Femoral and/or Popliteal Artery Lesions Using the IN.PACT Admiral™ Drug-Eluting Balloon.|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||April 2016|
|Estimated Study Completion Date :||August 2021|
Experimental: IN.PACT Admiral DEB
The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as "IN.PACT Admiral™ DEB")manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial.
Device: IN.PACT Admiral™ Drug Eluting Balloon
IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
- Primary Endpoint Clinical Cohort [ Time Frame: 12 months ]Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as: • Any re-intervention within the target lesion(s) due to symptoms or drop of ABI ≥ 20% or > 0.15 when compared to post-index procedure baseline ABI.
- Primary Safety Endpoint [ Time Frame: 12 months ]A composite of freedom from device- and procedure-related mortality through 30 days, freedom from major target limb amputation and TLR within 12 months post-index procedure.
- MAEs [ Time Frame: 12 months ]MAE (Major Adverse Events)is defined as all-cause mortality, clinically-driven TVR (Target Vessel Revascularization), major target limb amputation, thrombosis at the target lesion site.
- TLR [ Time Frame: 12 months ]Any Target lesion revascularisation
- TVR [ Time Frame: 12 months. ]Any Target vessel revascularisation
- Primary Sustained Clinical Improvement [ Time Frame: 12 months. ]Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.
- Device Success [ Time Frame: Index-procedure ]Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)
- Clinical Success [ Time Frame: prior to discharge ]Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01609296
Show 68 Study Locations
|Principal Investigator:||Gunnar Tepe, MD||Klinikum Rosenheim|
|Principal Investigator:||Gary Ansel, MD||MidOhio Cardiology and Vascular Consultants|
|Principal Investigator:||Marc Bosiers, MD||AZ Sint Blasius|
|Principal Investigator:||Do-Dai Do, MD||Swiss Cardiovascular Center, Inselspital|
|Principal Investigator:||Peter Gaines, MD||Sheffield Vascular Institute|
|Principal Investigator:||Alvaro Razuk, MD||Faculdade de Ciências Médicas da Santa Casa de Sao Paulo|